Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Avastin Versions Head For Debut; Watch Off-Label Space

Executive Summary

Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.

You may also be interested in...



Litigation Aside Biosimilar Avastin Just Got Cheaper In India

Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.

Litigation Aside Biosimilar Avastin Just Got Cheaper In India

Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.

Indian Avastin Biosimilar Arrives Amid Roche's Charges

Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel